| Basics |
Incyte Corp.
Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary therapeutics. Its product JAKAFI, a JAK1 and JAK2 inhibitor is used for treatment of patients with intermediate or high risk myelofibrosis.
|
| IPO Date: |
November 4, 1993 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$20.13B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.80 | 1.96%
|
| Avg Daily Range (30 D): |
$1.42 | 1.43%
|
| Avg Daily Range (90 D): |
$1.17 | 1.31%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.34M |
| Avg Daily Volume (30 D): |
2.11M |
| Avg Daily Volume (90 D): |
1.58M |
| Trade Size |
| Avg Trade Size (Sh.): |
104 |
| Avg Trade Size (Sh.) (30 D): |
49 |
| Avg Trade Size (Sh.) (90 D): |
47 |
| Institutional Trades |
| Total Inst.Trades: |
20,172 |
| Avg Inst. Trade: |
$4.71M |
| Avg Inst. Trade (30 D): |
$7.62M |
| Avg Inst. Trade (90 D): |
$8.31M |
| Avg Inst. Trade Volume: |
.08M |
| Avg Inst. Trades (Per Day): |
4 |
| Market Closing Trades |
| Avg Closing Trade: |
$14.9M |
| Avg Closing Trade (30 D): |
$33.56M |
| Avg Closing Trade (90 D): |
$31.7M |
| Avg Closing Volume: |
202.09K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$2.17
|
$2.09
|
|
Diluted EPS
|
|
$2.11
|
$2.04
|
|
Revenue
|
$
|
$ 1.37B
|
$ 1.22B
|
|
Gross Profit
|
$
|
$ 1.27B
|
$ 1.14B
|
|
Net Income / Loss
|
$
|
$ 424.17M
|
$ 405M
|
|
Operating Income / Loss
|
$
|
$ 443.52M
|
$ 530.31M
|
|
Cost of Revenue
|
$
|
$ 99M
|
$ 78.77M
|
|
Net Cash Flow
|
$
|
$ 500.04M
|
$ 13.43M
|
|
PE Ratio
|
|
|
|
|
|
|
